Acquisition furthers Astellas' commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma

Dr. Halit Bander named VP, Oncology, Medical Affairs; Moyra Knight named VP, Corporate Communications; Maribeth Landwehr named Executive Director, Corporate Communications

First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC

-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed-

Employees Also Raised More Than $55,000 at Third Annual "One Astellas Spirit Run" for Seven Charitable Organizations

-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study-

2018 Challenge Will Award a Total of $100,000 in New Grants to Help Reduce the Unequal Burden of Cancer

Joins Company's Executive Leadership Team

Asset Transfer was Completed on April 12, 2018

Dragovic was previously Vice President, Ethics & Compliance Americas

sNDA Seeks to Expand the Indication of XTANDI to include Men with Non-metastatic CRPC

Barretto-Ko was previously Senior Vice President, International Operations

Acquisition enables Astellas to fully utilize proprietary technology to produce pluripotent stem cells that have the potential to lower immunological rejection in numerous therapeutic areas